Context Therapeutics Inc. (CNTX)
- Previous Close
0.8696 - Open
0.8561 - Bid 0.8037 x 100
- Ask 0.8641 x 100
- Day's Range
0.8353 - 0.8979 - 52 Week Range
0.5500 - 2.7500 - Volume
32,020 - Avg. Volume
156,333 - Market Cap (intraday)
75.235M - Beta (5Y Monthly) 2.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4600 - Earnings Date Mar 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.75
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
www.contexttherapeutics.comRecent News: CNTX
View More
Performance Overview: CNTX
Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTX
View MoreValuation Measures
Market Cap
78.01M
Enterprise Value
-16.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.76%
Return on Equity (ttm)
-49.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-26.73M
Diluted EPS (ttm)
-0.4600
Balance Sheet and Cash Flow
Total Cash (mrq)
94.43M
Total Debt/Equity (mrq)
0.23%
Levered Free Cash Flow (ttm)
-36.03M